TWC
CTXR icon

TD Waterhouse Canada’s Citius Pharmaceuticals CTXR Stock Holding History

TD Waterhouse Canada’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-4
Closed -$3 – 2332
2025
Q4 		$3 Buy
+4
New +$5 ﹤0.01% 2031
2022
Q4 		– Sell
-3
Closed -$121 – 1716
2022
Q3 		$121 Hold
3
– – ﹤0.01% 1673
2022
Q2 		$81 Hold
3
– – ﹤0.01% 1721
2022
Q1 		$159 Hold
3
– – ﹤0.01% 1745
2021
Q4 		$150 Buy
+3
New +$136 ﹤0.01% 1712

Other funds holding CTXR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
AAG
Asset Advisory Group Kinnelon, New Jersey $229M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

TD Waterhouse Canada's CTXR Position: Q1 2026 in Review

TD Waterhouse Canada sold out of Citius Pharmaceuticals (CTXR) in Q1 2026, closing a stake of 4 shares — an estimated $3 sold.

TD Waterhouse Canada first reported a position in CTXR in Q4 2021 and held it in 5 quarters. The position peaked at $159 in Q1 2022. 38 funds tracked by Wall St. Rank hold CTXR as of Q1 2026.

  • TD Waterhouse Canada reported no remaining Citius Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • TD Waterhouse Canada sold 4 Citius Pharmaceuticals shares in Q1 2026, an estimated $3.
  • TD Waterhouse Canada first reported a position in Citius Pharmaceuticals in Q4 2021 and held it in 5 quarters.
  • TD Waterhouse Canada's Citius Pharmaceuticals position peaked at $159 in Q1 2022.
  • 38 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q1 2026.

Based on TD Waterhouse Canada's 13F filing for Q1 2026, filed 12 May 2026.